Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Epizyme (EPZM), Sensus Healthcare Inc (SRTS) and Conatus Pharmaceuticals (CNAT).
Epizyme (EPZM)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Epizyme, with a price target of $25. The company’s shares closed on Friday at $11.50.
Fein wrote:
“Our price target of $25 for EPZM is based on a probability-adjusted sum-of-the-parts NPV-DCF: $1.8 (Taz, DLBCL, EZH2mut) + $17.9 (Taz, FL) + $0.6 (Taz, INI- solid tumor) + $0.7 (DOT1L inhibitor) + $3.7 (cash).”
According to TipRanks.com, Fein is a 3-star analyst with an average return of 0.7% and a 40.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
Currently, the analyst consensus on Epizyme is a Strong Buy with an average price target of $22.67, which is a 97.1% upside from current levels. In a report issued on August 9, Cowen & Co. also maintained a Buy rating on the stock with a $18 price target.
See today’s analyst top recommended stocks >>
Sensus Healthcare Inc (SRTS)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Sensus Healthcare Inc today and set a price target of $10. The company’s shares closed on Friday at $5.87.
According to TipRanks.com, Chen has 0 stars on 0-5 star ranking scale with an average return of -19.1% and a 27.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Stealth Biotherapeutics Corp, and Aerpio Pharmaceuticals Inc.
Sensus Healthcare Inc has an analyst consensus of Moderate Buy, with a price target consensus of $10, representing a 70.4% upside. In a report issued on August 9, Maxim Group also maintained a Buy rating on the stock with a $11 price target.
Conatus Pharmaceuticals (CNAT)
H.C. Wainwright analyst Ed Arce maintained a Hold rating on Conatus Pharmaceuticals today. The company’s shares closed on Friday at $0.30, close to its 52-week low of $0.25.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 6.5% and a 34.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.
Conatus Pharmaceuticals has an analyst consensus of Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CNAT:
